Identification of candidate target genes of genomic aberrations in esophageal squamous cell carcinoma

TIAN-YUN SHEN, LI-LI MEI, YUN-TAN QIU and ZHI-ZHOU SHI

Faculty of Medicine, Kunming University of Science and Technology, Kunming, Yunnan 650500, P.R. China

Received June 26, 2015; Accepted July 12, 2016

DOI: 10.3892/ol.2016.4947

Abstract. The aim of the present study was to identify the candidate target genes of genomic aberrations in esophageal squamous cell carcinoma (ESCC). Array comparative genomic hybridization (CGH) and quantitative polymerase chain reaction were applied to analyze the copy number changes and expression level of candidate genes, respectively. Integrative analysis revealed that homozygous deletions of cyclin-dependent kinase inhibitor (CDKN) 2A and CDKN2B and gains of fascin actin-bundling protein 1 (FSCN1) and homer scaffolding protein 3 (HOMER3) occurred frequently in ESCC. The results demonstrated that the homozygous deletion of CDKN2A or CDKN2B was significantly associated with lymph node metastasis. Notably, the expression of CDKN2A and CDKN2B was lower in dysplasia than in normal esophageal epithelium. We also observed that the copy number increase of FSCN1 was significantly associated with pT, pN and pStage, and that the gain of HOMER3 was significantly linked with pN and pStage. We further revealed that FSCN1 and HOMER3 were overexpressed in ESCC, and that their overexpression was correlated with copy number increase. In conclusion, CDKN2A, CDKN2B, FSCN1 and HOMER3 are candidate cancer-associated genes and may play a tumorigenic role in ESCC.

Introduction

Esophageal squamous cell carcinoma (ESCC) is one of the most malignant types of cancer and is ranked as the sixth most common cause of cancer-associated mortality in the world, with a high incidence in China (1,2). Although diagnostic methods and cancer therapies have been improved in recent years, the prognosis remains poor due to widespread lymph node metastasis and frequent distant metastasis. Therefore, the identification and understanding of candidate target genes of genomic aberrations underlying esophageal carcinogenesis and metastasis may provide a new treatment target in ESCC.

ESCC is a multi-step process, and genomic aberration is a characteristic attribute. Several studies have identified that losses of 9p21.3, 16p13.3 and 18q22-qter and gains of 5p15, 7p22.1, 11q13.3 and 19p13.11 were the most frequent genomic aberrations in ESCC (3-5). Functional studies identified a number of candidate target driver genes of genomic aberration. For example, genomic loss and hypermethylation of nc886 (noncoding RNA) were detected in ESCC, and ectopically expressed nc886 could inhibit proliferation of ESCC cells (6). Togashi et al (7) also reported that oral cancer overexpressed 1 (ORAOV1) located at 11q13 was amplified in 53% of ESCC patients, and its amplification was significantly associated with poor differentiation status. Overexpression of ORAOV1 could enhance tumorigenicity and tumor growth (7). Thus, the identification of candidate tumor-associated genes is crucial in revealing the mechanism of tumorigenesis of esophageal cancer.

In the present study, we integratively analyzed the array comparative genomic hybridization (CGH) data and observed that homozygous deletions of cyclin-dependent kinase inhibitor (CDKN) 2A (9p21.3) and CDKN2B (9p21.3) and gains of fascin actin-bundling protein 1 (FSCN1) (7p22.1) and homer scaffolding protein 3 (HOMER3) (19p13.11) occurred frequently in ESCC. We further analyzed the correlations between the copy number changes of CDKN2A, CDKN2B, FSCN1, HOMER3 and clinical factors, and investigated the expression level of these genes in ESCC samples.

Materials and methods

Patients and samples. Freshly resected tissues from 115 ESCC patients were collected at the Department of Pathology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China. All of the esophageal cancer patients were treated with radical surgery, and none of them received any treatment prior to surgery. Representative tumor regions were excised by experienced pathologists and immediately stored at -70°C until use.

Biopsy tissues were taken from symptom-free patients during endoscopic screening for esophageal cancer in Linzhou,
China, which is a well-recognized high-risk area for ESCC. During endoscopy, the entire esophagus was visually examined and biopsies were taken from all focal lesions. If no focal lesions were detected, a standard site in the mid-esophagus was sampled.

All the samples used in this study were residual specimens following diagnostic sampling. Every patient signed separate informed consent forms for sampling and molecular analysis. The clinicopathological characteristics of patients are shown in Table I. This study was approved by the Ethics Committee of Kunming University of Science and Technology (Kunming, Yunnan, China).

**Microarray data analysis.** We integratively analyzed the array CGH data of 79 ESCC cases using Genomic Workbench (Agilent Technologies, Santa Clara, CA, USA) and MD-SeeGH (www.flintbox.ca). Genomic Workbench was used to calculate the log₂ratio for every probe and identify genomic aberrations. The mean log₂ratio of all probes in a chromosome region between 0.25 and 0.75 was classified as a genomic gain, >0.75 as an amplification, ≤0.25 as a hemizygous loss, and ≤0.75 as homozygous deletion.

**Quantitative polymerase chain reaction (qPCR).** qPCR was used to detect the expression level of candidate genes. The PCR reactions were performed in a total volume of 20 µl, including 10 µl 2X Power SYBR®-Green PCR master mix (Applied Biosystems, Warrington, UK), 2 µl cDNA (5 ng/µl) and 1 µl primer mix (10 µM each). The PCR amplification and detection were carried out in a LightCycler 480 II (Roche Applied Science, Manheim, Germany) as follows: initial denaturation at 95°C for 10 min; 40 cycles of 95°C for 15 sec and 60°C for 1 min. The relative expression was calculated using the comparative CT method. The expression of the target gene normalized to an endogenous reference (GAPDH) and relative to the calibrator was given by the formula 2^−ΔΔCq. ΔCT was calculated by subtracting the average GAPDH CT from the average CT of the gene of interest. The ratio defines the level of relative expression status of the target gene to that of GAPDH. The following primer pairs were used for the PCR assay: CDKN2A forward, 5' -CTT CCT GGA CAC GCT GGTTG -3', CDKN2A reverse, 5' -AAT CGG GGA TGT CTG AGG GA-3'; CDKN2B forward, 5' -CGG GGA CTA GTG GAG AAG GTG-3', CDKN2B reverse, 5' -CCA TCA TCA TGA CCT GGA TCGC-3'; FSCN1 forward, 5'-CAA AAA GTG TGC CTT CCG TACC-3', FSCN1 reverse, 5' -CCC ATT CTT CTT GGA GGT CACA-3'; HOMER3 forward, 5' -CCA AGG ACC AGG AGA TTC AGAC-3', HOMER3 reverse, 5'-AGC TCA CTC AGC TCA AAC AGG-3'; GAPDH forward, 5' -AAA TCC CAT CAC CAT CTT CCAG-3', GAPDH reverse, 5' -GAG TCC TTC CAC GAT ACC AAA GTTG-3'.

**Statistical analysis.** Statistical analyses were conducted using Student's t-tests and Chi-square tests using the statistical

---

**Table I. Correlations between copy number changes of genes and clinical factors.**

<table>
<thead>
<tr>
<th>Factors</th>
<th>CDKN2A</th>
<th>CDKN2B</th>
<th>FSCN1</th>
<th>HOMER3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HD</td>
<td>No HD</td>
<td>P-value</td>
<td>Gain</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>0.764</td>
<td>0.777</td>
<td>0.387</td>
<td>1.000</td>
</tr>
<tr>
<td>Female</td>
<td>0.804</td>
<td>0.098</td>
<td>1.000</td>
<td>0.102</td>
</tr>
<tr>
<td>Age</td>
<td>0.586</td>
<td>0.795</td>
<td>0.002</td>
<td>0.130</td>
</tr>
<tr>
<td>≤60</td>
<td>0.207</td>
<td>0.146</td>
<td>0.000</td>
<td>0.000</td>
</tr>
<tr>
<td>&gt;60</td>
<td>0.371</td>
<td>0.233</td>
<td>0.282</td>
<td>0.284</td>
</tr>
<tr>
<td>pT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1-T2</td>
<td>0.003</td>
<td>0.011</td>
<td>0.022</td>
<td>0.013</td>
</tr>
<tr>
<td>T3-T4</td>
<td>0.764</td>
<td>0.777</td>
<td>0.387</td>
<td>1.000</td>
</tr>
<tr>
<td>pN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>0.003</td>
<td>0.011</td>
<td>0.022</td>
<td>0.013</td>
</tr>
<tr>
<td>N1</td>
<td>0.371</td>
<td>0.233</td>
<td>0.282</td>
<td>0.284</td>
</tr>
<tr>
<td>pStage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>0.764</td>
<td>0.777</td>
<td>0.387</td>
<td>1.000</td>
</tr>
<tr>
<td>III</td>
<td>0.003</td>
<td>0.011</td>
<td>0.022</td>
<td>0.013</td>
</tr>
<tr>
<td>pGrade</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G1</td>
<td>0.003</td>
<td>0.011</td>
<td>0.022</td>
<td>0.013</td>
</tr>
<tr>
<td>G2</td>
<td>0.371</td>
<td>0.233</td>
<td>0.282</td>
<td>0.284</td>
</tr>
<tr>
<td>G3</td>
<td>0.003</td>
<td>0.011</td>
<td>0.022</td>
<td>0.013</td>
</tr>
</tbody>
</table>

CDKN, cyclin-dependent kinase inhibitor; FSCN1, fascin actin-bundling protein 1; HOMER3, homer scaffolding protein 3; HD, homozygous deletion.
software SPSS version 15.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Homozygous deletion of CDKN2A and CDKN2B in ESCC.** By integrative analysis of array CGH data from 79 ESCC cases, we observed that CDKN2A and CDKN2B were homozygously deleted in 18.6% of cases (Fig. 1). We further analyzed the correlations between copy number decreases of CDKN2A as well as CDKN2B and clinical parameters, and observed that homozygous deletion of CDKN2A or CDKN2B was significantly associated with lymph node metastasis (P=0.003 and P=0.0011, respectively; Table I). There were no correlations between homozygous deletion of CDKN2A or CDKN2B and gender, age, pT, pStage or pGrade (Table I). Most significantly, we analyzed the expression of CDKN2A and CDKN2B in precancerous lesions, and observed that the expression of these two genes was lower in dysplasia than in normal esophageal epithelium (P=0.024 and P=0.048, respectively; Fig. 2).

**Gains of FSCN1 and HOMER3 in ESCC.** By integrative analysis of array CGH data from 79 ESCC cases, we observed that gains of FSCN1 and HOMER3 were detected in 41 and 80% of patients, respectively (Fig. 3). We further analyzed the correlations between gains of FSCN1 or HOMER3 and clinical factors, and observed that gain of FSCN1 was significantly associated with pT, pN and pStage (P=0.002, P=0.022 and P=0.000, respectively; Table I). In addition, gain of HOMER3 was significantly linked with pN and pStage (P=0.013 and P=0.000, respectively; Table I). We further revealed through qPCR assay that FSCN1 and HOMER3 were overexpressed in ESCC, and the expression level in patients with gains was significantly higher than that in patients without gains (Fig. 4).

**Discussion**

Genomic aberrations are one of the mechanisms resulting in gene dysfunction, and contribute to carcinogenesis and tumor progression. Differentially expressed genes associated with DNA copy number changes may be candidate targets of amplifications or homozygous deletions, and play significant roles in tumorigenesis and the development of cancer (8).

9p21.3 is the most common loss in numerous types of cancer, including glioblastoma, esophageal cancer and pancreatic cancer (9,10), and is also the most frequent early event in the tumorigenesis of Epstein-Barr virus-associated nasopharyngeal carcinoma (11). CDKN2A and CDKN2B were identified as the driver genes of 9p21.3 loss. CDKN2A and CDKN2B are frequently inactivated in a number of cancer types. In lung cancer, CDKN2A is frequently inactivated via homozygous deletions, the methylation of the promoter region, or point mutations (12). In rectal cancer, Kohonen-Corish et al...
observed that CDKN2A methylation occurred in 20% of patients, and that CDKN2A methylation was associated with poor overall survival (13). CDKN2A hypermethylation is also associated with lymphovascular invasion, lymph
node metastasis and proximal tumor location in colorectal cancer (14). In ovarian cancer, deletion of CDKN2A is also a common event (15). Our study identified that homozygous deletion of CDKN2A or CDKN2B was significantly associated with lymph node metastasis. Most significantly, the expression of CDKN2A and CDKN2B was lower in dysplasia than in normal esophageal epithelium. These results indicate that CDKN2A and CDKN2B may play a significant role in the early formation of esophageal cancer.

Our study also revealed that FSCN1 and HOMER3, which were gained in ESCC, were overexpressed, and higher expression levels of these two genes were associated with copy number increase. The literature reveals that the expression of FSCN1 is an independent poor prognostic factor according to a multivariate analysis, and co-expression with MMP14 correlates with the poorest overall survival in esophageal cancer. The knockdown of FSCN1 inhibits the proliferation and invasion of ESCC cells (16). Chen et al (17) reported that FSCN1 was overexpressed in colorectal cancers, and was associated with cancer cell progression. Hanker et al (18) observed that lower FSCN1 expression was associated with significantly poorer overall survival in epithelial ovarian cancer. In tumors, FSCN1 could be directly targeted and regulated by miR-133a, miR-133b, miR-143 and miR-145 (19-22). Fuse et al (23) further revealed that restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. HOMER3 is a member of the cytoplasmic scaffolding proteins family, and regulates transcription and plays an essential role in the development and differentiation of certain tissues, including muscle and nervous systems (24-26). HOMER3 is overexpressed in acute myeloid leukemia (AML), and decreased expression of HOMER3 is associated with poor prognosis in AML (27,28). Li et al (29) further reported that forced expression of HOMER3 in K562 cells could inhibit proliferation, influence the cell cycle, and affect apoptosis induced by As2O3 via inhibition of Bel-2 expression. However, the roles of FSCN1 and HOMER3 were previously unclear in esophageal carcinogenesis.

In summary, our study suggested that CDKN2A, CDKN2B, FSCN1 and HOMER3 were candidate cancer-associated genes and may play a tumorigenic role in ESCC.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (grant no. 81460425), the Yunnan Provincial Research Foundation for Basic Research, China (grant no. 2013FD012), the Foundation for the Talents of Kunming University of Science and Technology (grant no. KKSY201260099) and Yunnan Provincial Engineering Center of Translational Cancer Medicine (grant no. 2011DH011).

References


